L Blonde

Summary

Affiliation: Ochsner Clinic Foundation
Country: USA

Publications

  1. ncbi request reprint Current challenges in diabetes management
    Lawrence Blonde
    Ochsner Clinical Research Unit, Section of Endocrinology, Department of Internal Medicine Ochsner Clinic Foundation New Orleans, Louisiana 70115, USA
    Clin Cornerstone 7:S6-17. 2005
  2. ncbi request reprint Improving care for patients with type 2 diabetes: applying management guidelines and algorithms, and a review of new evidence for incretin agents and lifestyle intervention
    Lawrence Blonde
    Ochsner Medical Center, Department of Endocrinology, 1514 Jefferson Hwy, New Orleans, LA, USA
    Am J Manag Care 17:S368-76. 2011
  3. ncbi request reprint Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors
    Lawrence Blonde
    Director, Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA
    Postgrad Med 126:172-89. 2014
  4. ncbi request reprint Patient management strategies in type 2 diabetes: current practices and future considerations
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes and Metabolic Diseases, Ochsner Clinic Foundation, Brent House, Room 629, 1514 Jefferson Hway, New Orleans, LA 70121, USA
    J Manag Care Pharm 11:S12-8. 2005
  5. ncbi request reprint New concepts in diabetes: how multihormonal regulation can improve glycemic control
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes and Metabolic Diseases, Ochsner Clinical Foundation, New Orleans, Louisiana 70121, USA
    J Manag Care Pharm 10:S3-8; quiz S9, S11-2. 2004
  6. doi request reprint Fixed-dose combinations for treatment of type 2 diabetes mellitus
    Lawrence Blonde
    Department of Endocrinology, Diabetes and Metabolic Diseases, Ochsner Medical Center, New Orleans, LA 70121, USA
    Adv Ther 29:1-13. 2012
  7. doi request reprint Benefits and risks for intensive glycemic control in patients with diabetes mellitus
    Lawrence Blonde
    Department of Endocrinology, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Med Sci 343:17-20. 2012
  8. pmc Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
    Sean D Sullivan
    Pharmaceutical, Outcomes Research and Policy Program, University of Washington, Seattle, USA
    Cardiovasc Diabetol 8:12. 2009
  9. ncbi request reprint Easing the transition to insulin therapy in people with type 2 diabetes
    Lawrence Blonde
    Diabetes Clinical Research Unit, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Diabetes Educ 33:232S-240S. 2007
  10. ncbi request reprint State of diabetes care in the United States
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA 70121, USA
    Am J Manag Care 13:S36-40. 2007

Detail Information

Publications47

  1. ncbi request reprint Current challenges in diabetes management
    Lawrence Blonde
    Ochsner Clinical Research Unit, Section of Endocrinology, Department of Internal Medicine Ochsner Clinic Foundation New Orleans, Louisiana 70115, USA
    Clin Cornerstone 7:S6-17. 2005
    ....
  2. ncbi request reprint Improving care for patients with type 2 diabetes: applying management guidelines and algorithms, and a review of new evidence for incretin agents and lifestyle intervention
    Lawrence Blonde
    Ochsner Medical Center, Department of Endocrinology, 1514 Jefferson Hwy, New Orleans, LA, USA
    Am J Manag Care 17:S368-76. 2011
    ..In addition, the feasibility of matching patients to appropriate lifestyle intervention, for both diabetes and diabetes prevention, is increasing...
  3. ncbi request reprint Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors
    Lawrence Blonde
    Director, Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA
    Postgrad Med 126:172-89. 2014
    ..Conclusion: The glycemic benefits of glargine use compared with alternative therapeutic options are maintained without excess hypoglycemia in patients with CVRFs. ..
  4. ncbi request reprint Patient management strategies in type 2 diabetes: current practices and future considerations
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes and Metabolic Diseases, Ochsner Clinic Foundation, Brent House, Room 629, 1514 Jefferson Hway, New Orleans, LA 70121, USA
    J Manag Care Pharm 11:S12-8. 2005
    ....
  5. ncbi request reprint New concepts in diabetes: how multihormonal regulation can improve glycemic control
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes and Metabolic Diseases, Ochsner Clinical Foundation, New Orleans, Louisiana 70121, USA
    J Manag Care Pharm 10:S3-8; quiz S9, S11-2. 2004
    ..Some of these novel multihormonal glucoregulatory therapies will likely soon become important components of the diabetes armamentarium. It is therefore important that managed care pharmacy decision makers learn about them...
  6. doi request reprint Fixed-dose combinations for treatment of type 2 diabetes mellitus
    Lawrence Blonde
    Department of Endocrinology, Diabetes and Metabolic Diseases, Ochsner Medical Center, New Orleans, LA 70121, USA
    Adv Ther 29:1-13. 2012
    ..Although several fixed-dose combinations (FDCs) are available, representing standard types of combination therapy in T2DM, use of these products has been limited...
  7. doi request reprint Benefits and risks for intensive glycemic control in patients with diabetes mellitus
    Lawrence Blonde
    Department of Endocrinology, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Med Sci 343:17-20. 2012
    ..Writing groups convened by these organizations have also developed treatment algorithms to help clinicians appropriately use both lifestyle and pharmacotherapy interventions to safely achieve glycemic targets...
  8. pmc Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
    Sean D Sullivan
    Pharmaceutical, Outcomes Research and Policy Program, University of Washington, Seattle, USA
    Cardiovasc Diabetol 8:12. 2009
    ..Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs. We sought to estimate the long-term consequences of liraglutide and rosiglitazone both added to glimepiride...
  9. ncbi request reprint Easing the transition to insulin therapy in people with type 2 diabetes
    Lawrence Blonde
    Diabetes Clinical Research Unit, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Diabetes Educ 33:232S-240S. 2007
  10. ncbi request reprint State of diabetes care in the United States
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA 70121, USA
    Am J Manag Care 13:S36-40. 2007
    ..With the advent of new incretin-related therapies, some of these concerns may be addressed. Diabetes is of growing concern, and better knowledge of treatment options and goals should be a priority for all healthcare professionals...
  11. ncbi request reprint Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials
    Lawrence Blonde
    Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Curr Med Res Opin 22:2111-20. 2006
    ..e., hypertension, dyslipidemia, and smoking)...
  12. ncbi request reprint Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes and Metabolic Diseases, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    J Am Acad Nurse Pract 18:524-33. 2006
    ..To provide nurse practitioners (NPs) a review of current practice guidelines that help clinicians' efforts to reduce the morbidity and mortality associated with diabetes and its major macrovascular complications...
  13. ncbi request reprint What are incretins, and how will they influence the management of type 2 diabetes?
    Lawrence Blonde
    Ochsner Diabeed Clinical Research Unit, Department of Internal Medicine, Ochsner Clinic Foundation, 1514 Jefferson Hwy, New Orleans, LA 70121, USA
    J Manag Care Pharm 12:S2-12; quiz S14-6. 2006
    ....
  14. doi request reprint The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
    L Blonde
    Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Ochsner Medical Center, New Orleans, LA, USA
    Diabetes Obes Metab 11:26-34. 2009
    ..Liraglutide was associated with a low risk of hypoglycaemia and was generally well tolerated. The majority of adverse effects were gastrointestinal, the most frequent of which was nausea...
  15. doi request reprint Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study
    L Blonde
    Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolic Diseases, Ochsner Medical Center, New Orleans, LA, USA
    Diabetes Obes Metab 11:623-31. 2009
    ..9-5.0 mmol/l (70-90 mg/dl)] using a patient-directed, treat-to-target algorithm for once-daily basal insulin in insulin-naïve subjects with type 2 diabetes suboptimally treated with oral antidiabetes drugs (OADs)...
  16. doi request reprint Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study
    L Blonde
    Department of Endocrinology, Diabetes and Metabolism, Ochsner Medical Center, New Orleans, LA 70121, USA
    Diabetes Obes Metab 11:978-86. 2009
    ..To assess the efficacy and tolerability of vildagliptin compared with thiazolidinediones (TZDs) as an add on to metformin treatment in a primary care patient population with type 2 diabetes...
  17. doi request reprint Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolism, Ochsner Medical Center, New Orleans, LA 70121, USA
    Cleve Clin J Med 76:S4-11. 2009
    ..Both classes have been shown to significantly reduce hyperglycemia. GLP-1 receptor agonists also promote significant weight loss and have potentially beneficial effects on cardiovascular risk markers...
  18. doi request reprint Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolism, Ochsner Medical Center, New Orleans, Louisiana 70121, USA
    Am J Med 123:S12-8. 2010
    ..Virtually all recognize that type 2 diabetes is a multifaceted disease, necessitating an integrated yet individualized approach to patient care...
  19. ncbi request reprint Defining and measuring quality of diabetes care
    L Blonde
    Department of Internal Medicine, Section on Endocrinology, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Prim Care 26:841-55. 1999
    ..This article defines the components of quality of diabetes care provision and discusses approaches to their measurement individually and globally...
  20. ncbi request reprint Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy
    L Blonde
    Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Diabetes Obes Metab 4:368-75. 2002
    ..To compare the efficacy, safety and tolerability of a fixed combination glyburide/metformin preparation with those of glyburide or metformin alone in patients with type 2 diabetes inadequately controlled by sulphonylurea, diet and exercise...
  21. ncbi request reprint Current evidence regarding the value of self-monitored blood glucose testing
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes and Metabolic Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Med 118:20S-26S. 2005
    ..Although additional work is needed to establish optimal frequency and timing of SMBG, these studies can serve as a basis for conservative recommendations to guide patients and their healthcare providers...
  22. ncbi request reprint Durable efficacy of metformin/glibenclamide combination tablets (Glucovance) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy
    L Blonde
    Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Int J Clin Pract 58:820-6. 2004
    ..No patient withdrew or required pharmacologic intervention for hypoglycaemia. Metformin-glibenclamide combination tablets are an effective and well-tolerated therapeutic option for intensifying oral anti-diabetic therapy...
  23. ncbi request reprint Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin
    L Blonde
    Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Diabetes Obes Metab 5:424-31. 2003
    ..A cohort of patients with type 2 diabetes, prescribed glyburide/metformin tablets, experienced significantly greater improvements in glycaemic control compared to patients receiving glyburide co-administered with metformin...
  24. ncbi request reprint Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    L Blonde
    Ochsner Clinic Foundation, New Orleans, LA, USA
    Diabetes Obes Metab 8:436-47. 2006
    ..This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET)...
  25. doi request reprint Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents
    L Blonde
    Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolism, Ochsner Medical Center, New Orleans, LA, USA
    Diabetes Obes Metab 14:20-32. 2012
    ..In clinical trials, liraglutide has shown efficacy and tolerability and resulted in certain significant benefits when compared with exenatide and sitagliptin...
  26. ncbi request reprint Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care
    Lawrence Blonde
    Ochsner Clinic Foundation, New Orleans, LA, USA
    J Clin Psychiatry 69:741-8. 2008
    ....
  27. doi request reprint The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical pract
    S Del Prato
    Ochsner Health System, New Orleans, LO, USA
    Diabet Med 25:662-70. 2008
    ..To examine the impact of inhaled human insulin (Exubera, EXU) on patient or physician willingness to adopt insulin after oral glucose-lowering agent failure...
  28. ncbi request reprint Thiazolidinediones in the treatment of managed care patients with type 2 diabetes
    Ram Pathak
    Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    Am J Manag Care 8:S483-94. 2002
    ..A number of studies have shown that a strategy of aggressive use of pharmacologic agents to achieve glycemic control is associated with cost benefits...
  29. ncbi request reprint Does home-based exercise improve body mass index in patients with type 2 diabetes? Results of a feasibility trial
    M A Krousel-Wood
    Ochsner Clinic Foundation, Center for Health Research, New Orleans, LA 70121, United States
    Diabetes Res Clin Pract 79:230-6. 2008
    ..This feasibility trial evaluated the use, safety, and short-term benefits of a home-based exercise intervention designed to increase physical activity among adults with diabetes...
  30. ncbi request reprint Internet resources to improve health care for patients with diabetes
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Section on Endocrinology, Diabetes, and Metabolic Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    Endocr Pract 12:131-7. 2006
    ..To review diabetes-related Web sites and online resources for health-care professionals, patients, and health-care organizations...
  31. pmc Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
    A Garber
    Department of Medicine and the Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA
    Diabetes Obes Metab 13:348-56. 2011
    ..Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and efficacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years...
  32. ncbi request reprint Case presentation: a patient with type 2 diabetes
    Lawrence Blonde
    Department of Endocrinology, Diabetes and Metabolic Diseases, Ochsner Clinic Foundation, New Orleans, LA, USA
    Diabetes Educ 33:114S-6S; quiz 117S. 2007
  33. ncbi request reprint Classification of diabetes mellitus
    A A Kazi
    Department of Ophthalmology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    Clin Lab Med 21:1-13. 2001
    ....
  34. ncbi request reprint The road ahead in diabetes management
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Ochsner Clinic Foundation, New Orleans, LA, USA
    Am J Manag Care 11:S167-9. 2005
  35. ncbi request reprint Best practices in diabetes management: getting more patients to goal
    Lawrence Blonde
    Ochsner Diabetes Clinical Research Unit, Ochsner Clinic Foundation, New Orleans, LA, USA
    Am J Manag Care 11:S186-8. 2005
  36. ncbi request reprint Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
    Lawrence Blonde
    Department of Internal Medicine, Oschner Clinic Foundation, New Orleans, LA, USA
    Curr Med Res Opin 20:565-72. 2004
    ..This retrospective chart review examined the overall gastrointestinal (GI) tolerability of both formulations...
  37. ncbi request reprint Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force
    Paul S Jellinger
    Endocr Pract 13:260-8. 2007
  38. ncbi request reprint Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes
    Lawrence Blonde
    Diabetes Care 25:245-6. 2002
  39. ncbi request reprint ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations
    Harold E Lebovitz
    Endocr Pract 12:6-12. 2006
  40. ncbi request reprint Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trial
    Jayant Dey
    JAMA 293:2597-8; author reply 2598. 2005
  41. ncbi request reprint Metabolic issues in patients with severe mental illness
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    South Med J 98:714-20. 2005
    ..Collaborative treatment between a psychiatrist and an endocrinologist is encouraged. The primary care physician may be required to fulfill both roles...
  42. ncbi request reprint New directions for type 2 diabetes mellitus management
    Lawrence Blonde
    Am J Manag Care 8:S437-40. 2002
  43. ncbi request reprint Thalidomide-associated hyperglycemia and diabetes: case report and review of literature
    Ram D Pathak
    Diabetes Care 26:1322-3. 2003
  44. ncbi request reprint Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes
    Nick Freemantle
    Department of Primary Care and General Practice, Primary Care Clinical Sciences Building, University of Birmingham Edgbaston, Birmingham B15 2TT UK
    Diabetes Care 28:427-8. 2005
  45. ncbi request reprint Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial
    Priscilla A Hollander
    Baylor University Medical Center, Endocrinology Center, 3600 Gaston Ave, Wadley Tower, Dallas, TX 75246, USA
    Diabetes Care 27:2356-62. 2004
    ....
  46. ncbi request reprint The Hurricane Katrina aftermath and its impact on diabetes care: observations from "ground zero": lessons in disaster preparedness of people with diabetes
    William T Cefalu
    Division of Nutrition and Chronic Diseases, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Rd, Baton Rouge, Louisiana 70808, USA
    Diabetes Care 29:158-60. 2006
  47. ncbi request reprint Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Harold Bays
    L MARC Research Center, Medical Director President, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 4:871-95. 2006
    ..This review describes how adiposopathy interventions may affect fat function, and thus improve EFRMD...